

What it claimed is:

1. A composition in the form of a free flowing, compressible powder that facilitates dissolution and water dispersion of poorly soluble or insoluble compounds.
2. The composition of claim 1 comprising a solid lipid or a solid lipid mixture that dissolves water-insoluble or poorly soluble compounds and is able to be absorbed by a porous powder or a mixture of porous powders at melt state, and forms solutions, micelles, microemulsion or emulsion with the compounds in an aqueous medium.
3. The composition of claim 1 comprising a porous powder or a mixture of porous powders that absorb melted lipids.
4. The composition of claim 1 comprising, at least, a compound that dissolves in the lipids and forms solutions, micelles, microemulsion or emulsion with the lipids in an aqueous medium.
5. The composition of claim 1 wherein said the composition facilitates formation of solutions, micelles, microemulsions or emulsions of poorly soluble or water-insoluble compounds and the lipids after administration with no need of pre-emulsification of the compounds during formulation.
6. The composition of claim 2 wherein the lipids are amphiphilic compounds.
7. The composition of claim 6, wherein the lipid is Gelucire, vitamin E TPGS, Bay 10, fatty acids, phospholipids, or non-phospholipids.

8. The composition of claim 3, wherein the porous powders are nontoxic solids possessing sufficient specific surface area and pore structure .
- 5 9. The composition of claim 8, wherein the surface area is bigger than 100 m<sup>2</sup>/g.
- 10 10. The composition of claim 8, wherein the pore structure has a diameter less than 50 nm).
11. The composition of claim 10, wherein the pore structure is alumina, silica or cellulose derivatives
12. The composition of claim 4, wherein the compound is  
15 cyclosporine, triamterene, acyclovir, doxorubicin, labetalol, doxepin, methyldopa or pentoxifill.
13. A pharmaceutical composition comprising the composition of claim 1-12 and a pharmaceutically  
20 acceptable carrier.
14. A method for producing the composition of claim 1, comprising steps of:
  - 25 d) Dissolving the said compound in melted lipid or lipid mixtures;
  - e) Impregnating the said porous powders with the drug-lipid melt; and
  - 30 f) Solidifying the drug-lipid melt absorbed in the porous powders by cooling, thereby producing the composition.
15. The method of claim 14, further comprising granulation, capsule filling, tableting, coating and paste making of the produced composition.
- 35 16. The composition produced by the method of claim 14.

17. A pharmaceutical composition which comprises the composition of claim 16.
- 5 18. The composition of claim 16, formulated in powders, capsules, granules, coated granules, tablets or coated tablets.
- 10 19. The formulated composition of claim 18, comprising the excipients selected from the group containing binders, diluents, disintegrants, coating material, and lubricants.